Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2026-02-20 @ 7:01 AM
Study NCT ID:
NCT00554502
Status:
COMPLETED
Last Update Posted:
2015-09-22
First Post:
2007-10-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Sponsor:
RWTH Aachen University
Organization:
Study Overview
Official Title:
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STOP-IgAN
Brief Summary:
* Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN
* Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.
* Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.
Detailed Description:
The best treatment of glomerular diseases of the kidney is currently not well defined. This study aims to answer if in patients with IgA nephropathy, the most common type of glomerulonephritis an immunosuppressive treatment (with the use of steroids and chemotherapy) added to a supportive treatment is more effective than a supportive treatment alone (with the use of drugs lowering the blood pressure and the urinary protein loss).
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: